Citi raised the firm’s price target on Ardelyx (ARDX) to $14 from $11 and keeps a Buy rating on the shares. The company’s outlook for $1B in annual Ibsrela revenue by 2029 is faster acceleration than Citi previously modeled, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx price target raised to $17 from $14 at BTIG
- Ardelyx: Strengthening Commercial Trajectory, Expanded IP Protection to 2041, and Pipeline Upside Support Raised $17 Buy Target
- Ardelyx upgraded to Overweight from Neutral at Piper Sandler
- Ardelyx price target raised to $19 from $16 at Raymond James
- Ardelyx files procedural regulatory disclosure update notice